-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion begins experimental testing of two AI-Immunology autoimmune treatment concepts

PUBT·09/14/2026 12:04:51
Listen to the news
Evaxion begins experimental testing of two AI-Immunology autoimmune treatment concepts
  • Evaxion expanded its AI-Immunology platform into autoimmune diseases, testing two new treatment concepts in experimental studies.
  • Initial results have not been presented yet; the company plans to present experimental data on November 18, 2026 at PEGS Europe.
  • The programs aim to target underlying disease drivers, seeking improved efficacy with fewer side effects than current symptom-focused therapies.
  • Management framed the move as a strategic expansion into a high unmet-need area with partnership potential across drug development stages.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800PRIMZONEFULLFEED1001262521) on September 14, 2026, and is solely responsible for the information contained therein.